Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Conference News AHA 2016

误诊 NOAC 在日常实践中很常见，并对中风和出血有影响

Shelley Wood

November 21, 2016

News Conference News AHA 2016

Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding

Shelley Wood

November 21, 2016

News Conference News AHA 2016

Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias

Shelley Wood

November 21, 2016

News Conference News ESC 2016

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Michael O'Riordan

August 28, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients

Todd Neale

January 25, 2016

News Daily News

研究肯定了 Watchman 左心耳封堵器减少卒中的成本效益

L.A. McKeown

December 14, 2015

News Daily News

Un Estudio Confirma la Rentabilidad del Dispositivo Watchman para el Cierre del AAI en el Descenso de ACV

L.A. McKeown

December 14, 2015

News Daily News

Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction

L.A. McKeown

December 14, 2015

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

Advertisement

误诊 NOAC 在日常实践中很常见，并对中风和出血有影响

Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding

Errar la Dosis de NOAC en la Práctica Clínica Diaria es algo Habitual, lo cual tiene Implicaciones en Materia de ACV y Hemorragias

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients

研究肯定了 Watchman 左心耳封堵器减少卒中的成本效益

Un Estudio Confirma la Rentabilidad del Dispositivo Watchman para el Cierre del AAI en el Descenso de ACV

Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content